Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$673,000.

  • Mereo BioPharma Group's Change in Accured Expenses rose 15.03% to -$673,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$839,000, marking a year-over-year increase of 61.85%. This contributed to the annual value of -$1.2 million for FY2024, which is 67.89% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Change in Accured Expenses is -$673,000, which was down 134.87% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Change in Accured Expenses ranged from a high of $4.2 million in Q2 2023 and a low of -$3.1 million during Q1 2023.
  • In the last 3 years, Mereo BioPharma Group's Change in Accured Expenses had a median value of -$706,000 in 2024 and averaged -$185,000.
  • Examining YoY changes over the last 5 years, Mereo BioPharma Group's Change in Accured Expenses showed a top increase of 58.79% in 2024 and a maximum decrease of 442.47% in 2024.
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Change in Accured Expenses stood at -$1.7 million in 2023, then soared by 58.79% to -$706,000 in 2024, then grew by 15.03% to -$673,000 in 2025.
  • Its Change in Accured Expenses stands at -$673,000 for Q3 2025, versus $1.9 million for Q2 2025 and -$1.4 million for Q1 2025.